These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 9635946)
1. Improved prognosis for biomarkers in breast cancer. Dowsett M Lancet; 1998 Jun; 351(9118):1753-4. PubMed ID: 9635946 [No Abstract] [Full Text] [Related]
2. [Estrogen and progesterone receptors in breast cancer]. Sonoo H Nihon Rinsho; 2000 Apr; 58 Suppl():146-53. PubMed ID: 11025988 [No Abstract] [Full Text] [Related]
3. [Prognostic factors in breast cancer and their consequences for therapeutic decisions]. Graeff H; Jänicke F Chirurg; 1992 Jun; 63(6):461-8. PubMed ID: 1643982 [No Abstract] [Full Text] [Related]
4. [Immunohistochemical markers of hormone sensitivity of breast carcinoma]. Simone G; Paradiso A Pathologica; 1992; 84(1094):11-4. PubMed ID: 1300527 [No Abstract] [Full Text] [Related]
5. Prognostic factors and therapeutic decisions in axillary node-negative breast cancer. Elledge RM; McGuire WL Annu Rev Med; 1993; 44():201-10. PubMed ID: 8476242 [TBL] [Abstract][Full Text] [Related]
6. Can biological markers improve the management of breast cancer patients? Biomarkers Ad-hoc Group of the United Kingdom Coordinating Committee on Cancer Research. Written on behalf of the Biomarkers Ad-hoc Group of the United Kingdom Coordinating Committee on Cancer Research Br J Cancer; 2000 May; 82(10):1625-6. PubMed ID: 10817494 [No Abstract] [Full Text] [Related]
7. [Biomarkers, tumor markers and prognostic markers in breast cancer]. Kurebayashi J Nihon Rinsho; 2006 Mar; 64(3):461-6. PubMed ID: 16529036 [TBL] [Abstract][Full Text] [Related]
8. [Value of detection of hormone receptors by biochemical and immunochemical methods in therapeutic decision for breast cancer]. Goussard J Bull Cancer; 1996 Dec; 83(12):1031-6. PubMed ID: 9116370 [TBL] [Abstract][Full Text] [Related]
9. Predictive value of estrogen receptor status as assessed by ligand-binding assay in patients with early-stage breast cancer treated with breast conserving surgery and radiation therapy. Takei H; Horiguchi J; Maemura M; Koibuchi Y; Oyama T; Yokoe T; Iino Y; Morishita Y Oncol Rep; 2002; 9(2):375-8. PubMed ID: 11836611 [TBL] [Abstract][Full Text] [Related]
10. [Significance of the proliferative activity of breast cancer for prognosis and therapy]. Pickartz H Z Arztl Fortbild (Jena); 1991 Oct; 85(20):993-4. PubMed ID: 1776291 [No Abstract] [Full Text] [Related]
11. [Tumor markers in screening, diagnosis and treatment of patients with breast carcinoma]. Thomas CM; Wobbes T; Bonfrer JM; Peterse JL; Nap M; Beex LV Ned Tijdschr Geneeskd; 1993 Nov; 137(46):2354-7. PubMed ID: 8264818 [No Abstract] [Full Text] [Related]
12. [Which biomarkers can we use?]. Nogi H; Uchida K; Kobayashi T Nihon Rinsho; 2012 May; 70(5):816-20. PubMed ID: 22620006 [TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor testing of breast cancer in current clinical practice: what's the question? Schnitt SJ J Clin Oncol; 2006 Apr; 24(12):1797-9. PubMed ID: 16567766 [No Abstract] [Full Text] [Related]
14. Biological markers in breast cancer prognosis and treatment. Kesisis G; Kontovinis LF; Gennatas K; Kortsaris AH J BUON; 2010; 15(3):447-54. PubMed ID: 20941809 [TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor determination and long term survival of patients with carcinoma of the breast. Crowe JP; Gordon NH; Hubay CA; Shenk RR; Zollinger RM; Brumberg DJ; McGuire WL; Shuck JM Surg Gynecol Obstet; 1991 Oct; 173(4):273-8. PubMed ID: 1925896 [TBL] [Abstract][Full Text] [Related]
16. [Clinical significance of bone marrow micrometastases of breast tumors]. Dubecz S; Csuka O; Török K; Vasas N; Péley G; Doleschal Z; Sulyok Z; Láng I; Köves I Magy Seb; 2003 Aug; 56(3-4):108-12. PubMed ID: 14619093 [TBL] [Abstract][Full Text] [Related]
17. [Estrogen and progesterone receptors in breast cancer]. Cohen Y; Borovik R Harefuah; 1985 Dec; 109(11):350-2. PubMed ID: 3912300 [No Abstract] [Full Text] [Related]
18. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. Yu H; Levesque MA; Clark GM; Diamandis EP Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775 [TBL] [Abstract][Full Text] [Related]